NASDAQHealth CareMedical Instruments & SuppliesSnapshot 2026-07-23
Reading HBIO? Create a free portfolio, then add this holding for ongoing Reports and tracking. Track it in a free portfolio. No credit card.
Create your account →A long-form read on the 1–3 year hold thesis. Slower and deeper than the daily snapshot — it refreshes only when the evidence moves.
This is a speculative growth investment with a focus on recovery. The company has shown strong recent financial performance but remains loss-making, indicating a high-risk profile.
The market currently prices HBIO as cheap compared to its peers, with a notable expectations gap. This suggests that investors are not fully accounting for the potential upside from its recent momentum and sector tailwinds.
Management's focus on revenue growth and margin improvement has been consistent, but recent results indicate challenges in delivering these goals. The company's earnings quality remains weak, which adds to the uncertainty.
Key factors include the performance of sector bellwethers like ISRG, MDLN, and BDX, which could influence HBIO's trajectory. Additionally, any changes in guidance during upcoming earnings calls could significantly impact investor sentiment.
Overall, the next 1-3 years will depend heavily on management's ability to execute on their priorities and external market conditions. Not investment advice.
The most important moves since the prior daily snapshot.
Our read on the company is unchanged since the prior snapshot.
as of 2026-07-23
Specific, dated things to watch for, each with what would confirm it and what would prove it wrong.
Not investment advice. Scores describe historical and current data; they are not forecasts of future returns. Consult a licensed advisor before making investment decisions.
Why it matters: Earnings results will show how much revenue is growing. They will also show margin performance.
Confirms one read:Earnings report shows revenue growth and margin improvement.
Confirms the other:Earnings report shows revenue decline and margin pressure.
Why it matters: Mid-single digit growth is key to meeting the full-year growth target of 2% to 4%.
Confirms:Q2 revenue was between $20.5 million and $22.5 million. This shows mid-single digit growth.
Disproves:Q2 revenue below $20.5 million, indicating a decline in growth.
Why it matters: If the health care sector's revenue growth speeds up, it could help Harvard Bioscience. This would signal a better environment for the company.
Confirms:Health care sector revenue growth returns to near 10 percent or higher.
Disproves:The health care sector's revenue growth is slowing down. It is below current levels.
Why it matters: Meeting this target would show Harvard Bioscience is on track for growth. It is key for investor confidence.
Confirms:Q2 revenue growth of 2% to 4% year over year.
Disproves:Q2 revenue growth below 2% year over year.
Why it matters: This project is important. It helps make things run better and costs less.
Confirms:Management gives a clear update on Project Viking. It shows that progress is being made.
Disproves:No updates or negative news on Project Viking's status.
Why it matters: Achieving this margin range is crucial for maintaining the full-year margin target of 58% to 60%.
Confirms:Adjusted gross margin reported between 57% and 59% for Q2.
Disproves:Adjusted gross margin is below 57%. This shows pressure on making money.
